The tumor suppressor p53 is a transcription factor that controls the expression of hundreds of genes. Emerging evidence suggests that the p53-induced RNA-binding protein ZMAT3 is a key splicing ...

Gene expression leading to alterations in the DNA caused by asbestos exposure may explain the development of Malignant Pleural Mesothelioma (MPM), a rare and aggressive cancer.

More information: Zhihua Lin et al, Electromagnetic wireless remote control of mammalian transgene expression, Nature Nanotechnology (2025). DOI: 10.1038/s41565-025-01929-w ...

A study published today in the journal Cell marks the first reported instance of generative AI designing synthetic molecules that can successfully control gene expression in healthy mammalian cells.

We report the corresponding pharmacodynamic (PD) effects of EZH2 inhibition and tumor gene expression changes by M+E in patients with mCRPC. Methods: Serial whole blood and paired tumor biopsy samples ...

“The biggest aha -moment for me has been that being stressed for even 5 to 10 minutes can reshape my biology at the level of gene expression,” says Slavich. Social Safety Theory Based on these ...

Manipulating Gene Expression to Treat Disease Several of our scientists study gene regulation in specific cancers, including cancers of the blood, lung, pancreas and prostate. They seek treatment ...

Gene expression in the human brain: cell types become more specialized, not just more numerous Date: January 2, 2025 Source: University of California - Santa Barbara Summary: Our brain is arguably ...

“These AI tools have immense potential for designing genetic switches that precisely tune gene expression for novel applications, such as biomanufacturing and therapeutics, that lie outside the ...

The unidentified student's diagram suggested that his heart had five girls in it, namely: Haritha, Piya, Roopa, Namitha, and Pooja. He didn't stop just with labelling.

Following the FDA nod, Elevidys was the first-ever approved gene therapy for DMD. The label expansion is mainly supported by data from the phase III EMBARK study, announced last October.

The FDA has expanded the label for Sarepta's Duchenne muscular dystrophy gene therapy Elevidys to all patients age 4 and older.